The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Histone deacetylase inhibitors: from target to clinical trials
Abstract
Transformed cells, characterised by inappropriate cell proliferation, do not necessarily lose the capacity to undergo growth arrest under certain stimuli. DNA, genetic information, is packaged in chromatin proteins, for example, histones. The structure of chromatin may be altered by post-translational modifications (e.g., acetylation, phosphorylation, methylation and ubiquitylation) which play a role in regulating gene expression. Two groups of enzymes, histone deacetylases (HDACs) and acetyl transferases, determine the acetylation status of histones. This review focuses on compounds that inhibit HDAC activity. These agents have been shown to be active in vitro and in vivo in causing cancer cell growth arrest, differentiation and/or apoptosis. Several HDAC inhibitors are currently in clinical trials as anticancer agents and, in particular, hydroxamic acid-based HDAC inhibitors have shown activity against cancers at well-tolerated doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756 · cited 6×
“The hypothesis is that the multiprotein complexes of transcription factors that activate or repress gene expression ‘read the code’ [3,6].”
BackgroundInfluentialCrystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain
Bannister, A. J., Zegerman, P., Partridge, J. F., Miska, E. A., Thomas, J. O., Allshire, R. C., & Kouzarides, T. (2001) · Nature · doi:10.1038/35065138 · Cited by 2,903
Regulation of chromatin structure by site-specific histone H3 methyltransferases
Rea, S., Eisenhaber, F., O'Carroll, D., Strahl, B. D., Sun, Z.-W., Schmid, M., Opravil, S., Mechtler, K., Ponting, C. P., Allis, C. D., et al. (2000) · Nature · doi:10.1038/35020506 · Cited by 2,845
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 7×
“* For references see text and reviews [2,19,68].”
BackgroundInfluentialSelf-citationCameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Roth, S. Y., Denu, J. M., & Allis, C. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.81 · Cited by 1,845
Acetylation of Histones and Transcription-Related Factors
Sterner, D. E., & Berger, S. L. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.2.435-459.2000 · Cited by 1,780
Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758
Role of Histone H3 Lysine 9 Methylation in Epigenetic Control of Heterochromatin Assembly
Nakayama, J.-I., Rice, J. C., Strahl, B. D., Allis, C. D., & Grewal, S. I. S. (2001) · Science · doi:10.1126/science.1060118 · Cited by 1,739
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Self-citationHistone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A
Yang, X.-J., Ogryzko, V. V., Nishikawa, J.-I., Howard, B. H., & Nakatani, Y. (1996) · Nature · doi:10.1038/382319a0 · Cited by 1,479
Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins
Frye, R. A. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3000 · Cited by 1,409
Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase
Nagy, L., Kao, H.-Y., Chakravarti, D., Lin, R. J., Hassig, C. A., Ayer, D. E., Schreiber, S. L., & Evans, R. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80218-4 · Cited by 1,230
A complex containing N-CoR, mSln3 and histone deacetylase mediates transcriptional repression
Heinzel, T., Lavinsky, R. M., Mullen, T.-M., Söderström, M., Laherty, C. D., Torchia, J., Yang, W.-M., Brard, G., Ngo, S. D., Davie, J. R., et al. (1997) · Nature · doi:10.1038/387043a0 · Cited by 1,214
Histone acetylation and an epigenetic code
Turner, B. M. (2000) · BioEssays · doi:10.1002/1521-1878(200009)22:9<836::aid-bies9>3.0.co;2-x · Cited by 1,182
Acetylation: a regulatory modification to rival phosphorylation?
Kouzarides, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.6.1176 · Cited by 1,160
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Self-citationp53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage.
Macleod, K. F., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kinzler, K., Vogelstein, B., & Jacks, T. (1995) · Genes & Development · doi:10.1101/gad.9.8.935 · Cited by 1,119
Richon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090
Self-citationSignaling to Chromatin through Histone Modifications
Cheung, P., Allis, C. D., & Sassone-Corsi, P. (2000) · Cell · doi:10.1016/s0092-8674(00)00118-5 · Cited by 989
The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases
Landry, J., Sutton, A., Tafrov, S. T., Heller, R. C., Stebbins, J., Pillus, L., & Sternglanz, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.110148297 · Cited by 970
Robertson, K. D., Ait-Si-Ali, S., Yokochi, T., Wade, P. A., Jones, P. L., & Wolffe, A. P. (2000) · Nature Genetics · doi:10.1038/77124 · Cited by 942
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Self-citationRetinoblastoma protein represses transcription by recruiting a histone deacetylase
Magnaghi-Jaulin, L., Groisman, R., Naguibneva, I., Robin, P., Lorain, S., Le Villain, J. P., Troalen, F., Trouche, D., & Harel-Bellan, A. (1998) · Nature · doi:10.1038/35410 · Cited by 909
Suzuki, H., Gabrielson, E., Chen, W., Anbazhagan, R., van Engeland, M., Weijenberg, M. P., Herman, J. G., & Baylin, S. B. (2002) · Nature Genetics · doi:10.1038/ng892 · Cited by 857
Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression
Alland, L., Muhle, R., Hou, H., Potes, J., Chin, L., Schreiber-Agus, N., & DePinho, R. A. (1997) · Nature · doi:10.1038/387049a0 · Cited by 844
Jones, R. (2002) · Nature Reviews Genetics · doi:10.1038/nrg962 · Cited by 828
Three proteins define a class of human histone deacetylases related to yeast Hda1p
Grozinger, C. M., Hassig, C. A., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4868 · Cited by 770 · cited 2×
“HDACs 4, 5, 7 and 9 share homology in two regions, the C-terminal catalytic domain and a N-terminal regulatory domain [2,9,38-40].”
BackgroundGao, L., Cueto, M. A., Asselbergs, F., & Atadja, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111871200 · Cited by 744 · cited 1×
“Recently, HDAC 11 was cloned and characterised [41].”
BackgroundHistone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S.-K., Chung, H. Y., et al. (2001) · Nature Medicine · doi:10.1038/86507 · Cited by 731
Ito, K., Barnes, P. J., & Adcock, I. M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.18.6891-6903.2000 · Cited by 723
Yoshida, M., Horinouchi, S., & Beppu, T. (1995) · BioEssays · doi:10.1002/bies.950170510 · Cited by 713
Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 694
Erythroleukemic Differentiation
Marks, P. A., & Rifkind, R. A. (1978) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.47.070178.002223 · Cited by 680
Self-citation(1996) · Europe PMC (PubMed Central) · Cited by 659
Histone deacetylases, transcriptional control, and cancer
Cress, W. D., & Seto, E. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200007)184:1<1::aid-jcp1>3.0.co;2-7 · Cited by 621
Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon‐Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2000) · PubMed · Cited by 615
Self-citationMutations truncating the EP300 acetylase in human cancers
Gayther, S. A., Batley, S. J., Linger, L., Bannister, A., Thorpe, K., Chin, S.-F., Daigo, Y., Russell, P., Wilson, A., Sowter, H. M., et al. (2000) · Nature Genetics · doi:10.1038/73536 · Cited by 587
Core-binding factors in haematopoiesis and leukaemia
Speck, N. A., & Gilliland, D. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc840 · Cited by 569
Lu, J., McKinsey, T. A., Zhang, C.-L., & Olson, E. N. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00025-3 · Cited by 547
The Human Histone Deacetylase Family
Gray, S. G., & Ekström, T. J. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5080 · Cited by 546
Histone deacetylase inhibitors as new cancer drugs
Marks, P. A., Richon, V. M., Breslow, R., & Rifkind, R. A. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00010 · Cited by 531
Self-citationKijima, M., Yoshida, M., Sugita, K., Horinouchi, S., & Beppu, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41547-5 · Cited by 514
Wang, J., Hoshino, T., Redner, R. L., Kajigaya, S., & Liu, J. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10860 · Cited by 512
Butler, L. M., Zhou, X., Xu, W.-S., Scher, H. I., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182372299 · Cited by 510
Self-citationSandor, V. A., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R. A., Piekarz, R., Tucker, E. E., Figg, W. D., et al. (2002) · PubMed · Cited by 502
Warrell, R. P., He, L.-Z., Richon, V., Calleja, E., & Pandolfi, P. P. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.21.1621 · Cited by 502
FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor
Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M., & Horinouchi, S. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4027 · Cited by 487
Murphy, M., Ahn, J., Walker, K. K., Hoffman, W. H., Evans, R. M., Levine, A. J., & George, D. L. (1999) · Genes & Development · doi:10.1101/gad.13.19.2490 · Cited by 455
Piekarz, R. L., Robey, R., Sandor, V., Bakke, S., Wilson, W. H., Dahmoush, L., Kingma, D. M., Turner, M. L., Altemus, R., & Bates, S. E. (2001) · Blood · doi:10.1182/blood.v98.9.2865 · Cited by 445
Ng (2000) · doi:10.1016/s0968-0004(00)01551-6 · Cited by 427
Genomewide studies of histone deacetylase function in yeast
Bernstein, B. E., Tong, J. K., & Schreiber, S. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.250477697 · Cited by 421
Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.
Richon, V. M., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., Civoli, F., Breslow, R., Rifkind, R. A., & Marks, P. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5705 · Cited by 420
Self-citationConjunction dysfunction: CBP/p300 in human disease
Giles, R. H., Peters, D. J. M., & Breuning, M. H. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(98)01438-3 · Cited by 403
Deroanne, C. F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.-M., Nusgens, B. V., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205108 · Cited by 400
Sambucetti, L. C., Fischer, D. D., Zabludoff, S., Kwon, P. O., Chamberlin, H., Trogani, N., Xu, H., & Cohen, D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34940 · Cited by 390
Functional significance of histone deacetylase diversity
Khochbin, S., Verdel, A., Lemercier, C., & Seigneurin-Berny, D. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00174-x · Cited by 366 · cited 7×
“HDACs 4, 5, 7 and 9 share homology in two regions, the C-terminal catalytic domain and a N-terminal regulatory domain [2,9,38-40].”
BackgroundInfluentialHistone acetylation and disease
Timmermann, S., Lehrmann, H., Polesskaya, A., & Harel-Bellan, A. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000896 · Cited by 341
BRCA1 interacts with components of the histone deacetylase complex
Yarden, R. I., & Brody, L. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4983 · Cited by 330
He, L.-Z., Tolentino, T., Grayson, P., Zhong, S., Warrell, R. P., Rifkind, R. A., Marks, P. A., Richon, V. M., & Pandolfi, P. P. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11537 · Cited by 303
Self-citationHistone deacetylase inhibitors in cancer treatment
Vigushin, D. M., & Coombes, R. C. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200201000-00001 · Cited by 301
Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide Derivatives
Suzuki, T., Ando, T., Tsuchiya, K., Fukazawa, N., Saito, A., Mariko, Y., Yamashita, T., & Nakanishi, O. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980565u · Cited by 293
Vrana, J. A., Decker, R. H., Johnson, C. R., Wang, Z., Jarvis, W. D., Richon, V. M., Ehinger, M., Fisher, P. B., & Grant, S. (1999) · Oncogene · doi:10.1038/sj.onc.1203176 · Cited by 284
Acetylation control of the retinoblastoma tumour-suppressor protein
Chan, H. M., Krstic-Demonacos, M., Smith, L., Demonacos, C., & Thangue, N. B. L. (2001) · Nature Cell Biology · doi:10.1038/35083062 · Cited by 282
Histone Acetylation and Chromatin Remodeling
Gregory, P. D., Wagner, K., & Hörz, W. (2001) · Experimental Cell Research · doi:10.1006/excr.2001.5187 · Cited by 274
Histone deacetylase as a therapeutic target
Krämer, O. H., Göttlicher, M., & Heinzel, T. (2001) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00438-6 · Cited by 257
Molecular Cloning and Characterization of a Novel Histone Deacetylase HDAC10
Guardiola, A. R., & Yao, T.-P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109861200 · Cited by 253 · cited 1×
“HDAC 6 and the more recently described HDAC 10, have two regions of homology with the Class II catalytic site [9,40,42-44].”
BackgroundCloning and characterization of a histone deacetylase, HDAC9
Zhou, X., Marks, P. A., Rifkind, R. A., & Richon, V. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191375098 · Cited by 245
Self-citationOxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
Kim, Y. B., Lee, K.-H., Sugita, K., Yoshida, M., & Horinouchi, S. (1999) · Oncogene · doi:10.1038/sj.onc.1202564 · Cited by 232
Jones, R. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn993 · Cited by 209
Gilbert, J., Baker, S. D., Bowling, M. K., Grochow, L. B., Figg, W. D., Zabelina, Y., Donehower, R. C., & Carducci, M. A. (2001) · PubMed · Cited by 206
Histone Acetylation at Promoters Is Differentially Affected by Specific Activators and Repressors
Deckert, J., & Struhl, K. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.8.2726-2735.2001 · Cited by 206
Covalent modifications of histones: expression from chromatin templates
Davie, J. R. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80138-x · Cited by 199
Kwon, H. J., Owa, T., Hassig, C. A., Shimada, J., & Schreiber, S. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3356 · Cited by 197
Isolation and Characterization of Mammalian HDAC10, a Novel Histone Deacetylase
Kao, H.-Y., Lee, C.-H., Komarov, A., Han, C. C., & Evans, R. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108931200 · Cited by 193
Su, G. H., Sohn, T. A., Ryu, B., & Kern, S. E. (2000) · PubMed · Cited by 189
Histone Acetylation Modifiers in the Pathogenesis of Malignant Disease
Mahlknecht, U., & Hoelzer, D. (2000) · Molecular Medicine · doi:10.1007/bf03402044 · Cited by 180
Telomerase activation by histone deacetylase inhibitor in normal cells
Takakura, M., Kyo, S., Sowa, Y., Wang, Z., Yatabe, N., Maida, Y., Tanaka, M., & Inoue, M. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.14.3006 · Cited by 175
Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis
Kwon, H. J., Kim, M. S., Kim, M. J., Nakajima, H., & Kim, K. (2002) · International Journal of Cancer · doi:10.1002/ijc.1602 · Cited by 171
Chang, S. M., Kuhn, J. G., Rizzo, J., Robins, H. I., Schold, S. C., Spence, A. M., Berger, M. S., Mehta, M. P., Bozik, M. E., Pollack, I., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2188 · Cited by 166
Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment
Huang, L., & Pardee, A. B. (2000) · Molecular Medicine · doi:10.1007/bf03401823 · Cited by 164
Murata, T. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1071 · Cited by 163
Methylation Talk Between Histones and DNA
Bird, A. (2001) · Science · doi:10.1126/science.1066726 · Cited by 158
A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.
Thibault, A., Cooper, M. R., Figg, W. D., Venzon, D. J., Sartor, O. A., Tompkins, A. C., Weinberger, M., Headlee, D. J., Mccall, N., & Samid, D. (1994) · PubMed · Cited by 158
Conley, B. A., Egorin, M. J., Tait, N. S., Rosen, D. M., Sausville, E. A., Dover, G. H., Fram, R. J., & Echo, D. A. V. (1998) · PubMed · Cited by 155
Genes modulated by histone acetylation as new effectors of butyrate activity
Ragione, F. D., Criniti, V., Pietra, V. D., Borriello, A., Oliva, A., Indaco, S., Yamamoto, T., & Zappia, V. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02539-x · Cited by 148
Xiao, H., Hasegawa, T., & Isobe, K. (1999) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19990601)73:3<291::aid-jcb1>3.0.co;2-5 · Cited by 141
Isolation and Characterization of a Novel Class II Histone Deacetylase, HDAC10
Fischer, D. D., Cai, R. L., Bhatia, U., Asselbergs, F. A. M., Song, C., Terry, R., Trogani, N., Widmer, R., Atadja, P. W., & Cohen, D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108055200 · Cited by 140
Chronic Oral Administration of CI-994: A Phase I Study
Prakash, S., Foster, B. J., Meyer, M., Wozniak, A., Heilbrun, L. K., Flaherty, L. E., Zalupski, M. M., Radulovic, L. L., Valdivieso, M., & LoRusso, P. M. (2001) · Investigational New Drugs · doi:10.1023/a:1006489328324 · Cited by 136
Phase I study of phenylacetate administered twice daily to patients with cancer
Thibault, A., Samid, D., Cooper, M. R., Figg, W. D., Tompkins, A. C., Patronas, N. J., Headlee, D. J., Köhler, D., Venzon, D. J., & Myers, C. E. (1995) · Cancer · doi:10.1002/1097-0142(19950615)75:12<2932::aid-cncr2820751221>3.0.co;2-p · Cited by 129
Butyrate as a differentiating agent: pharmacokinetics, analogues and current status
Newmark, H. L., Lupton, J. R., & Young, C. W. (1994) · Cancer Letters · doi:10.1016/0304-3835(94)90023-x · Cited by 129
Histone acetylation and the cell-cycle in cancer
Wang, C., Fu, M., Mani, S., Wadler, S., Senderowicz, A. M., & Pestell, R. G. (2001) · Frontiers in bioscience · doi:10.2741/1wang1 · Cited by 121
Butler, L. M., Webb, Y., Agus, D. B., Higgins, B., Tolentino, T., Kutko, M. C., LaQuaglia, M. P., Drobnjak, M., Cordon‐Cardo, C., Scher, H. I., et al. (2001) · PubMed · Cited by 120
Self-citationJohnson, C. A., White, D. A., Lavender, J. S., O'Neill, L. P., & Turner, B. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107942200 · Cited by 119 · cited 1×
“There is evidence that HDACs may have different lysine substrate specificities [29,33,49].”
BackgroundZhou, D.-C., Kim, S. H., Ding, W., Schultz, C. L., Warrell, R. P., & Gallagher, R. E. (2002) · Blood · doi:10.1182/blood.v99.4.1356 · Cited by 118
Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate
Qiu, L., Kelso, M. J., Hansen, C. P., West, M. L., Fairlie, D. P., & Parsons, P. G. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690493 · Cited by 115
Gore, S. D., & Carducci, M. A. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.12.2923 · Cited by 109
Deviant nucleosomes: the functional specialization of chromatin
Wolffe, A. P., & Pruss, D. (1996) · Trends in Genetics · doi:10.1016/0168-9525(96)81401-6 · Cited by 102
Brinkmann, H., Dahler, A. L., Popa, C., Serewko-Auret, M. M., Parsons, P. G., Gabrielli, B. G., Burgess, A., & Saunders, N. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100206200 · Cited by 79
The synthesis of cyclic tetrapeptoid analogues of the antiprotozoal natural product apicidin
Murray, P. J., Kranz, M., Ladlow, M., Taylor, S., Berst, F., Holmes, A. B., Keavey, K., Jaxa‐Chamiec, A. A., Seale, P. W., Stead, P., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00049-x · Cited by 76
HDAC1, a Histone Deacetylase, Forms a Complex with Hus1 and Rad9, Two G2/M Checkpoint Rad Proteins
Cai, R. L., Yan‐Neale, Y., Cueto, M. A., Xu, H. W., & Cohen, D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000168200 · Cited by 75
Role of histone deacetylases in acute leukemia
Fenrick, R., & Hiebert, S. W. (1998) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(1998)72:30/31+<194::aid-jcb24>3.0.co;2-h · Cited by 73
Design and synthesis of a novel class of histone deacetylase inhibitors
Lavoie, R., Bouchain, G., Fréchette, S., Woo, S. H., Khalil, E. A., Leit, S. M., Fournel, M., Yan, P. T., Trachy-Bourget, M.-C., Beaulieu, C., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00552-2 · Cited by 67
Chang, S. M., Kuhn, J. G., Robins, H. I., Schold, S. C., Spence, A. M., Berger, M. S., Mehta, M. P., Bozik, M. E., Pollack, I., Schiff, D., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.984 · Cited by 61
Meinke, P. T., Colletti, S. L., Doss, G. A., Myers, R. W., Gurnett, A. M., Dulski, P. M., Darkin‐Rattray, S. J., Allocco, J., Galuska, S., Schmatz, D. M., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0001976 · Cited by 50
Kosugi, H., Ito, M., Yamamoto, Y., Towatari, M., Ito, M., Ueda, R., Saito, H., & Naoe, T. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb01126.x · Cited by 47
Smirnov, D. A., Hou, S., & Ricciardi, R. P. (2000) · Virology · doi:10.1006/viro.1999.0181 · Cited by 43
Parsons, P. G., Hansen, C. P., Fairlie, D. P., West, M. L., Danoy, P., Sturm, R. A., Dunn, I. S., Pedky, J., & Ablett, E. M. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00016-6 · Cited by 39
Uesato, S., Kitagawa, M., Nagaoka, Y., Maeda, T., Kuwajima, H., & Yamori, T. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00175-0 · Cited by 39
Chromatin organisation and human disease
Urnov, F. D., & Wolffe, A. P. (2000) · Emerging Therapeutic Targets · doi:10.1517/14728222.4.5.665 · Cited by 26
Glaser, K. B., Li, J., Aakre, M. E., Morgan, D. W., Sheppard, G. S., Stewart, K. D., Pollock, J. S., Lee, P., O'Connor, C. Z., Anderson, S. N., et al. (2002) · PubMed · Cited by 22
Cited by
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
“Dose-limiting toxicities include thrombocytopaenia, nausea and fatigue; in the case of depsipeptide, cardiac arrhythmia was additionally observe”
BackgroundGui, C.-Y., Ngo, L., Xu, W. S., Richon, V. M., & Marks, P. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307708100 · Cited by 550
Self-citationGene-promoter hypermethylation as a biomarker in lung cancer
Belinsky, S. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1432 · Cited by 533
Histone Deacetylase Inhibitors
Miller, T. A., Witter, D. J., & Belvedere, S. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0303094 · Cited by 530
Insinga, A., Monestiroli, S., Ronzoni, S., Gelmetti, V., Marchesi, F., Viale, A., Altucci, L., Nervi, C., Minucci, S., & Pelicci, P. G. (2005) · Nature Medicine · doi:10.1038/nm1160 · Cited by 516
Metadata
- Authors
- Kelly, W. K., O’Connor, O. A., & Marks, P. A.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2002-12
- Volume
- 11
- Issue
- 12
- Pages
- 1695-1713
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2135994759
- Cited by
- 253
- References
- 117
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.